aflibercept-ayyh (Pavblu) vs Surabgene lomparvovec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
aflibercept-ayyh (Pavblu)
Marketed by Amgen
NCT04270747 · Phase 3 · completed
This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.
Reported efficacy
Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)
Result source: NCT04270747
Surabgene lomparvovec
Developed by AbbVie and partners
NCT04832724 · Phase 2 · completed
The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
Reported efficacy
RGX-314 target protein concentration in aqueous humor (At Week 24): Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 (not_applicable)
Result source: NCT04832724
Results for Age-Related Macular Degeneration
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. aflibercept-ayyh (Pavblu): 4 of 4 rows · Surabgene lomparvovec: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | aflibercept-ayyh (Pavblu) | Surabgene lomparvovec |
|---|---|---|
| Dropout rate | 5.2%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 16.7%Cohort 1a NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results0%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 8.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.3%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | —Cohort 1a NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results—Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | —ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results8.1%Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.1%Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 33.3%Cohort 1a NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results33.3%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 25%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 33.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | neovascular age-related macular degeneration 5.9% conjunctival haemorrhage 1.5% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 1 more resultconjunctival haemorrhage 4.2% neovascular age-related macular degeneration 2.1% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | a intraocular inflammation 66.7% retinal haemorrhage 66.7% visual acuity reduced/impairment 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more resultsconjunctival haemorrhage 50% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 66.7% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 100% conjunctival haemorrhage 75% retinal thickening 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 91.7% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 91.7% eye irritation 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
aflibercept-ayyh (Pavblu)
show 8 more results
show 3 more results
show 7 more results
Surabgene lomparvovec
show 4 more results
show 4 more results
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aflibercept-ayyh (Pavblu)'s landscape · Surabgene lomparvovec's landscape